Description: Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Home Page: www.calliditas.se
Kungsbron 1, D5
Stockholm,
111 22
Sweden
Phone:
46 84 11 30 05
Officers
| Name | Title |
|---|---|
| Ms. Renee Aguiar-Lucander | Chief Exec. Officer |
| Mr. Fredrik Johansson | Chief Financial Officer |
| Dr. Katayoun Welin-Berger Ph.D. | VP of Operations |
| Dr. Johan Haggblad Ph.D. | Chief Scientific Officer |
| Mr. Mikael Widell | Head of Communications & IR |
| Mr. Jonathan A. Schur | Group Gen. Counsel |
| Ms. Sandra Frithiof | Head of HR |
| Ms. Ann-Kristin Myde BSc | Head of Clinical Devel. & VP of Project Management |
| Mr. Andrew B. Udell B.Sc., M.B.A. | Pres of North America Commercial |
| Dr. Krassimir Mitchev | Head of Medical Affairs |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 8.8261 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4307 |
| Price-to-Sales TTM: | 12.9805 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 98 |